常山药业(300255) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥647,277,328.34, a decrease of 12.65% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥2,528,324.29, down 94.96% year-on-year[7]. - The basic earnings per share (EPS) was ¥0.0027, reflecting a decline of 94.96% compared to the previous year[7]. - Total operating revenue for the current period is ¥1,793,779,750.02, a decrease of 17% compared to ¥2,158,441,271.38 in the previous period[28]. - The net profit for the current period is 61,239,360.42, a decrease from 205,052,547.28 in the previous period, representing a decline of approximately 70.1%[30]. - The total comprehensive income for the current period is 56,628,177.82, compared to 196,009,872.74 in the previous period, indicating a decrease of about 71.1%[33]. - The basic and diluted earnings per share for the current period are both 0.0720, down from 0.2215 in the previous period, reflecting a decline of approximately 67.5%[33]. - The operating profit for the current period is 86,207,188.49, a significant decrease from 232,565,881.24 in the previous period, reflecting a decline of about 62.9%[30]. - The total profit for the current period is 83,704,368.74, down from 231,578,978.91 in the previous period, indicating a decrease of approximately 63.8%[30]. Assets and Liabilities - Total assets increased by 11.07% to ¥5,764,437,750.03 compared to the end of the previous year[7]. - The company's total assets reached ¥5,764,437,750.03, up from ¥5,189,848,787.26, showing growth in asset base[27]. - Non-current liabilities increased to ¥701,618,091.58 from ¥383,684,965.68, indicating potential leverage for future investments[27]. - The total liabilities of the company are now ¥2,659,585,565.72, compared to ¥2,117,729,197.94 in the previous period, reflecting increased borrowing[27]. - The company's equity attributable to shareholders increased to ¥3,107,567,055.77 from ¥3,068,784,360.68, showing a slight growth in shareholder value[27]. Cash Flow - The company reported a net cash flow from operating activities of -¥183,723,082.26, a decrease of 29.24% year-to-date[7]. - Cash flow from operating activities shows a net outflow of -183,723,082.26, compared to -142,157,545.23 in the previous period, indicating a worsening cash flow situation[34]. - Cash inflow from financing activities is 1,859,945,742.67, an increase from 1,336,493,978.00 in the previous period, representing a growth of about 39.2%[36]. - The cash and cash equivalents at the end of the period amount to 384,734,470.51, down from 517,516,379.54 in the previous period, a decrease of approximately 25.7%[36]. Shareholder Information - The number of shares held by the largest shareholder, Gao Shuhua, is 333,644,728, representing 35.69% of total shares[14]. - The total number of shares held by the top ten shareholders includes 333,644,728 shares held by Gao Shuhua, representing the largest single holding[17]. - The company repurchased a total of 15,906,000 shares, accounting for 1.70% of the total share capital[17]. - The company plans to unlock 25% of the shares held by executives annually during their tenure, with specific unlock dates set for certain shareholders[18]. - The total number of restricted shares at the end of the period was 2,656,757, with a significant portion being released due to executive departures[20]. - The company reported a total of 11,500,000 shares held in a credit trading guarantee account by shareholder Chen Xi, indicating active participation in financing activities[17]. - The company has not disclosed any related party relationships among the top ten shareholders, nor whether they are acting in concert[17]. Expenses - Sales expenses decreased by 38.72% year-on-year, primarily due to reduced marketing expenses[13]. - Financial expenses increased by 43.25% year-on-year, mainly due to higher interest from increased bank loans[13]. - Research and development expenses increased to ¥115,423,336.21 from ¥106,404,718.54, indicating a continued focus on innovation[28]. Market Outlook - The company plans to expand its market presence and enhance product offerings in the upcoming quarters[29]. - The company reported a net profit margin improvement, indicating better cost management and operational efficiency[29].